![](/img/cover-not-exists.png)
Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial
Kim, D., Huber, R., Ahn, M., Langer, C., Tiseo, M., West, H., Groen, H., Reckamp, K., Hochmair, M., Leighl, N., Hansen, K.H., Gettinger, S., Paz-Ares Rodriguez, L., Kim, E., Smit, E., Kim, S., ReichmaVolume:
127
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/S0169-5002(19)30120-5
Date:
January, 2019
File:
PDF, 55 KB
english, 2019